Literature DB >> 12243242

Anti-inflammatory effects of the macrolides.

Ross Davidson1, Louis Péloquin.   

Abstract

Since their introduction into clinical practice, the macrolides have played an important role in the treatment of both upper and lower respiratory tract disease. In addition to their antibacterial effects, increased evidence is mounting to suggest that the macrolides possess other clinically relevant properties, such as anti-inflammatory and immunomodulatory activities. Several in vitro and clinical trials have been published supporting this hypothesis. This article reviews some of the evidence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243242     DOI: 10.2310/7070.2002.21285

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  4 in total

1.  Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.

Authors:  Tomoki Maekawa; Hikaru Tamura; Hisanori Domon; Takumi Hiyoshi; Toshihito Isono; Daisuke Yonezawa; Naoki Hayashi; Naoki Takahashi; Koichi Tabeta; Takeyasu Maeda; Masataka Oda; Athanasios Ziogas; Vasileia Ismini Alexaki; Triantafyllos Chavakis; Yutaka Terao; George Hajishengallis
Journal:  JCI Insight       Date:  2020-08-06

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

3.  Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.

Authors:  Qun-Li Ding; Dan Lv; Bi-Jiong Wang; Qiao-Li Zhang; Yi-Ming Yu; Shi-Fang Sun; Zhong-Bo Chen; Hong-Ying Ma; Zai-Chun Deng
Journal:  Exp Ther Med       Date:  2015-01-15       Impact factor: 2.447

4.  Clarithromycin and endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps: study protocol for the MACRO randomised controlled trial.

Authors:  Carl Philpott; Steffi le Conte; David Beard; Jonathan Cook; William Sones; Steve Morris; Caroline S Clarke; Mike Thomas; Paul Little; Jane Vennik; Valerie Lund; Helen Blackshaw; Anne Schilder; Stephen Durham; Spiros Denaxas; James Carpenter; James Boardman; Claire Hopkins
Journal:  Trials       Date:  2019-04-29       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.